Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤$202.9 million cash, equivalents and securities funds operations into Q2 2028
- ➤Phase 3 PTCL and Phase 2 atopic dermatitis enrollment remain on track
- ➤Angel Pharma completed cohort 1 enrollment; topline data expected March 2027
- ➤Phase 1b hidradenitis suppurativa trial enrolling; initial data expected 1H 2027
- ➤Q3 R&D expense rose to $17.8 million; net loss widened to $20.3 million
Expert Statements
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track
Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027
Get started
Create a free account to read the full story.